The site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identified definitively. We employed several strategies to address this question. First, McA RH7777 cells were pulse-labeled for 20 min with [35 S]methionine/cysteine and chased for 1 h (Chase I) to allow study of newly synthesized apoB100 LDL/HDL remaining in the endoplasmic reticulum (ER). After Chase I, cells were incubated for another hour (C2) with/without brefeldin A (BFA) and nocodazole (Noc) (to block ER to Golgi trafficking) and with/without oleic acid (OA). OA treatment alone during C2 increased VLDL secretion. This was prevented by the addition of BFA/Noc in C2. When C2 media were replaced by control media for another 1-h chase (C3), VLDL formed during OA treatment in C2 were secreted into C3 medium. Thus, OA-induced conversion of apoB100 LDL/HDL to VLDL during C2 occurred in the ER. Next, newly synthesized apoB100 lipoproteins were trapped in the Golgi by treatment with Noc and monensin during Chase I (C1), and C2 was carried out in the presence of BFA/Noc with/without OA and without monensin. Under these conditions, OA treatment during C2 did not stimulate VLDL secretion. The same pulse/chase protocols were followed by iodixanol subcellular fractionation, extraction of lipoproteins from ER and Golgi, and sucrose gradient separation of extracted lipoproteins. Cells treated with BFA/Noc and OA in C2 had VLDL in the ER. In the absence of OA, only LDL/HDL were present in the ER. The density of Golgi lipoproteins in these cells was not affected by OA. Similar results were obtained when ER were immuno-isolated with anti-calnexin antibodies. In conclusion, apoB100 bulk lipidation, resulting in conversion of LDL/HDL to VLDL, can occur in the ER, but not in the Golgi, in McA RH7777 cells.Although the early, crucial steps in apolipoprotein B100 (apoB100)-lipoprotein assembly, including translation, translocation, and targeting of apoB100 for the ubiquitin-proteasomal degradation pathway have been well studied (1), much less is known about how the mature, triglyceride (TG) 1 -enriched lipoprotein is assembled. Thus, the exact process of bulk lipid addition and, in particular, the site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) to form mature, TG-enriched very low density lipoproteins (VLDL) has not been identified definitively. Early work by Hamilton and co-workers using electron microscopy (2), suggests that a lipid-poor form of apoB present in the rough endoplasmic reticulum (ER) could fuse with lipid droplets present in the smooth ER. That work first raised the possibility that VLDL was assembled in a two-step process. This scheme has been supported by studies from several laboratories (3-5), including our own (6). The two-step model includes the transformation of an "HDL-like" apoB-lipoprotein to a TG-enriched lipoprotein in the presence of adequate cell ...